A Clinical Decision Tool for Risk Stratifying Patients with Systemic Sclerosis-Related Pulmonary Hypertension

Justin K. Lui(Boston University), Elizabeth S. Klings, Deepa M. Gopal(Boston University), Michael P. LaValley(Boston University), Andreea M. Bujor(Boston University), Ruchika Sangani(Boston University), Robert Smyth(Boston University), Kari R. Gillmeyer(Pulmonary and Allergy Associates), Renda Soylemez Wiener(Boston University), Marcin A. Trojanowski(Boston University)
Lung
November 13, 2023
10.1007/s00408-023-00646-2
Cited by 3

Related Papers

Screening for Lung Cancer
|CHEST Journal|2018|353
An Official American Thoracic Society Clinical Practice Guideline: Diagnosis, Risk Stratification, and Management of Pulmonary Hypertension of Sickle Cell Disease
|American Journal of Respiratory and Critical Care Medicine|2014|256
Screening for Lung Cancer
|CHEST Journal|2021|240
Effect of Canakinumab vs Placebo on Survival Without Invasive Mechanical Ventilation in Patients Hospitalized With Severe COVID-19
|JAMA|2021|166
Serum albumin concentration and heart failure risk
|American Heart Journal|2010|157